{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:16:10Z","timestamp":1793247370652,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A rapid, sensitive, and selective reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the simultaneous determination of five COVID-19 antiviral drugs: favipiravir, molnupiravir, nirmatrelvir, remdesivir, and ritonavir. The chromatographic separation was achieved on a Hypersil BDS C18 column (4.5\u2009\u00d7\u2009150\u00a0mm, 5\u00a0\u03bcm particle size) using an isocratic mobile phase consisting of water and methanol (30:70 v\/v, pH 3.0 adjusted with 0.1% ortho-phosphoric acid) at a flow rate of 1 mL\/min with UV detection at 230\u00a0nm. The optimized method demonstrated good chromatographic resolution with retention times of 1.23, 1.79, 2.47, 2.86, and 4.34\u00a0min for favipiravir, molnupiravir, nirmatrelvir, remdesivir, and ritonavir, respectively. The method was validated according to ICH guidelines, showing linearity in the concentration range of 10\u201350\u00a0\u00b5g\/mL with correlation coefficients (r\u00b2)\u2009\u2265\u20090.9997 for all analytes. The limits of detection were 0.415\u20130.946\u00a0\u00b5g\/mL, while the limits of quantification were 1.260\u20132.868\u00a0\u00b5g\/mL. The method demonstrated high trueness (99.59-100.08%) and precision (RSD\u2009&lt;\u20091.1%). The validated method was successfully applied to the determination of these drugs in their pharmaceutical formulations, with recovery values ranging from 99.98 to 100.7% and no significant interference from excipients. Comprehensive greenness and practicality evaluations using five assessment tools yielded favorable scores: AGREE (0.70), AGREEprep (0.59), MoGAPI (70%), BAGI (82.5), and CACI (79), indicating good environmental performance and excellent practical applicability for routine pharmaceutical quality control analysis. The multi-tool assessment confirmed the method\u2019s environmental friendliness through strategic solvent selection and minimal sample preparation requirements, while demonstrating superior practical implementation characteristics including cost-effectiveness and accessibility in standard analytical laboratories.<\/jats:p>","DOI":"10.1038\/s41598-025-09904-0","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:26:28Z","timestamp":1752549988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations"],"prefix":"10.1038","volume":"15","author":[{"given":"Mohamed W.","family":"Nassar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"9904_CR1","doi-asserted-by":"crossref","unstructured":"J.J.T.o.t.R.S.o.T.M. Whitworth, Hygiene, COVID-19: a fast evolving pandemic, in, Oxford University Press, pp. 241\u2013248. (2020).","DOI":"10.1093\/trstmh\/traa025"},{"key":"9904_CR2","doi-asserted-by":"crossref","unstructured":"W.S.T.C.J. N.E.j.o. medicine, Repurposed antiviral drugs for Covid-19\u2014interim WHO solidarity trial results,  384 497\u2013511. (2021).","DOI":"10.1056\/NEJMoa2023184"},{"key":"9904_CR3","doi-asserted-by":"crossref","unstructured":"Atmar, R. L. N.J.A.a. Finch, chemotherapy, new perspectives on antimicrobial agents: molnupiravir and nirmatrelvir\/ritonavir for treatment of COVID-19, 66 e02404-02421. (2022).","DOI":"10.1128\/aac.02404-21"},{"key":"9904_CR4","doi-asserted-by":"crossref","unstructured":"Khalil, H. A. & Hassanein, N. A. A.F.J.R.a. El-Yazbi, recent analytical methodologies for the determination of anti-covid-19 drug therapies in various matrices: a critical review, 13 13224\u201313239. (2023).","DOI":"10.1039\/D3RA00654A"},{"key":"9904_CR5","doi-asserted-by":"crossref","unstructured":"Konstantinova, I. D., LAndronova, V. & Fateev, I. V. R.S.J.A.n. Esipov, favipiravir and its structural analogs: antiviral activity and synthesis methods, 14 16. (2022).","DOI":"10.32607\/actanaturae.11652"},{"key":"9904_CR6","doi-asserted-by":"crossref","unstructured":"Maas, B. M. et al. Molnupiravir: Mechanism of action, clinical, and translational science, 17 e13732. (2024).","DOI":"10.1111\/cts.13732"},{"key":"9904_CR7","doi-asserted-by":"crossref","unstructured":"S.J.I.J.o.M, S. & Barik Inhibition of viral RNA-dependent RNA polymerases by nucleoside inhibitors: an illustration of the unity and diversity of mechanisms, 23 12649. (2022).","DOI":"10.3390\/ijms232012649"},{"key":"9904_CR8","doi-asserted-by":"crossref","unstructured":"Hashemian, S. M. R. et al. Pharmacotherapy, Paxlovid (Nirmatrelvir\/Ritonavir): A new approach to Covid-19 therapy? 162 114367. (2023).","DOI":"10.1016\/j.biopha.2023.114367"},{"key":"9904_CR9","doi-asserted-by":"crossref","unstructured":"Gerhart, J. et al. A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir\/ritonavir, 63 27\u201342. (2024).","DOI":"10.1007\/s40262-023-01339-y"},{"key":"9904_CR10","doi-asserted-by":"crossref","unstructured":"Bartels, I., Jaeger, M., Schmidt, T. C. J. A. & Chemistry, B. Determination of anti-SARS-CoV-2 virustatic pharmaceuticals in the aquatic environment using high-performance liquid chromatography high-resolution mass spectrometry, 415 5365\u20135377. (2023).","DOI":"10.1007\/s00216-023-04811-7"},{"key":"9904_CR11","unstructured":"Babu, A. V. S. & Sharma, H. J. E. C. B. Method development and validation of Ritonavir and nirmatrelvir in tablet dosage form by using RP-High performance liquid chromatography, 12 815\u2013825. (2023)."},{"key":"9904_CR12","doi-asserted-by":"publisher","first-page":"115131","DOI":"10.1016\/j.jpba.2022.115131","volume":"223","author":"G Tiris","year":"2023","unstructured":"Tiris, G., Gazioglu, I., Furton, K. G., Kabir, A. & Locatelli, M. Fabric phase sorptive extraction combined with high performance liquid chromatography for the determination of favipiravir in human plasma and breast milk. J. Pharm. Biomed. Anal. 223, 115131 (2023).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"9904_CR13","doi-asserted-by":"publisher","first-page":"e5365","DOI":"10.1002\/bmc.5365","volume":"36","author":"IA Abdallah","year":"2022","unstructured":"Abdallah, I. A. et al. A gadolinium-based magnetic ionic liquid for supramolecular dispersive liquid\u2013liquid Microextraction followed by HPLC\/UV for the determination of favipiravir in human plasma. Biomed. Chromatogr. 36, e5365 (2022).","journal-title":"Biomed. Chromatogr."},{"key":"9904_CR14","doi-asserted-by":"publisher","first-page":"123087","DOI":"10.1016\/j.jchromb.2021.123087","volume":"1189","author":"IA Abdallah","year":"2022","unstructured":"Abdallah, I. A., Hammad, S. F., Bedair, A. & Mansour, F. R. Menthol-assisted homogenous liquid-liquid Microextraction for HPLC\/UV determination of favipiravir as an antiviral for COVID-19 in human plasma. J. Chromatogr. B. 1189, 123087 (2022).","journal-title":"J. Chromatogr. B"},{"key":"9904_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4155\/bio-2021-0219","volume":"14","author":"IA Abdallah","year":"2022","unstructured":"Abdallah, I. A., Hammad, S. F., Bedair, A., Elshafeey, A. H. & Mansour, F. R. Determination of favipiravir in human plasma using homogeneous liquid\u2013liquid Microextraction followed by HPLC\/UV. Bioanalysis 14, 205\u2013216 (2022).","journal-title":"Bioanalysis"},{"key":"9904_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13065-023-01080-4","volume":"17","author":"IA Abdallah","year":"2023","unstructured":"Abdallah, I. A., Hammad, S. F., Bedair, A. & Mansour, F. R. Homogeneous liquid\u2013liquid Microextraction coupled with HPLC\/DAD for determination of nirmatrelvir and Ritonavir as COVID-19 combination therapy in human plasma. BMC Chem. 17, 166 (2023).","journal-title":"BMC Chem."},{"key":"9904_CR17","doi-asserted-by":"crossref","unstructured":"Martens-Lobenhoffer, J., B\u00f6ger, C. R. & Kielstein, J. S.M.J.J.o.C.B. Bode-B\u00f6ger, simultaneous quantification of nirmatrelvir and Ritonavir by LC-MS\/MS in patients treated for COVID-19, 1212 123510. (2022).","DOI":"10.1016\/j.jchromb.2022.123510"},{"key":"9904_CR18","doi-asserted-by":"crossref","unstructured":"Marzouk, H. M., Gouda, A. S., Rezk, M. R. & Abdel-Megied, A. M. J. M. J. A validated LC-MS\/MS method for determination of molnupiravir and favipiravir in human plasma; assessment of the remarkable potential synergistic effect against SARS-CoV-2 infection: application to a Pharmacokinetic study in healthy Egyptian volunteers, 109815. (2023).","DOI":"10.1016\/j.microc.2023.109815"},{"key":"9904_CR19","doi-asserted-by":"crossref","unstructured":"Nguyen, R. et al. W.D.J.J.o.C.B. Figg, development and validation of a simple, selective, and sensitive LC-MS\/MS assay for the quantification of Remdesivir in human plasma, 1171 122641. (2021).","DOI":"10.1016\/j.jchromb.2021.122641"},{"key":"9904_CR20","doi-asserted-by":"crossref","unstructured":"Xu, Z. et al. A validated LC-MS\/MS method for determination of six Anti-SARS-CoV-2 drugs in plasma and its application for a Pharmacokinetic study in rats, 1235 124038. (2024).","DOI":"10.1016\/j.jchromb.2024.124038"},{"key":"9904_CR21","doi-asserted-by":"crossref","unstructured":"Abdelazim, A. H. et al. Green adherent spectrophotometric determination of molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form, 285 121911. (2023).","DOI":"10.1016\/j.saa.2022.121911"},{"key":"9904_CR22","doi-asserted-by":"crossref","unstructured":"Elama, H. S. et al. Eco-friendly spectrophotometric methods for determination of remdesivir and favipiravir; the recently approved antivirals for COVID-19 treatment, 287 122070. (2023).","DOI":"10.1016\/j.saa.2022.122070"},{"key":"9904_CR23","unstructured":"Trivedi, C., Mardia, R., Suhagia, B. & J.I.J.o.P, S. Research, development and validation of spectrophotometric method for the Estimation of Ritonavir in tablet dosage form, 4 4567. (2013)."},{"key":"9904_CR24","doi-asserted-by":"publisher","first-page":"112198","DOI":"10.1016\/j.microc.2024.112198","volume":"207","author":"A Bedair","year":"2024","unstructured":"Bedair, A. et al. Aggregation-induced emission of hybrid microcrystalline cellulose\/metal\u2013organic framework for selective spectrofluorometric detection of nirmatrelvir. Microchem. J. 207, 112198 (2024).","journal-title":"Microchem. J."},{"key":"9904_CR25","doi-asserted-by":"publisher","first-page":"e40661","DOI":"10.1016\/j.heliyon.2024.e40661","volume":"10","author":"YA Saber","year":"2024","unstructured":"Saber, Y. A. et al. Garlic peel-based carbon quantum Dots as a sustainable alternative for the sensitive and green spectrofluorometric quantification of molnupiravir in pharmaceutical capsules. Heliyon 10, e40661 (2024).","journal-title":"Heliyon"},{"key":"9904_CR26","first-page":"100453","volume":"7","author":"FR Mansour","year":"2024","unstructured":"Mansour, F. R. et al. A microcrystalline cellulose\/metal-organic framework hybrid for enhanced Ritonavir dispersive solid phase Microextraction from human plasma. Carbohydr. Polym. Technol. Appl. 7, 100453 (2024).","journal-title":"Carbohydr. Polym. Technol. Appl."},{"key":"9904_CR27","doi-asserted-by":"publisher","first-page":"110397","DOI":"10.1016\/j.microc.2024.110397","volume":"200","author":"RE Kannouma","year":"2024","unstructured":"Kannouma, R. E., Kamal, A. H., Hammad, M. A. & Mansour, F. R. Incorporation of eggshell waste in the Preparation of carbon quantum Dot nanoprobes for the determination of COVID-19 antiviral drug; molnupiravir. Microchem. J. 200, 110397 (2024).","journal-title":"Microchem. J."},{"key":"9904_CR28","doi-asserted-by":"crossref","unstructured":"Elshenawy, E. A. & Mansour, F. R. Sustainable synthesis of Cu-doped carbon Dots from biomass waste for sensitive molnupiravir analysis in pharmaceutical capsules. Microchem. J., 113003. (2025).","DOI":"10.1016\/j.microc.2025.113003"},{"key":"9904_CR29","doi-asserted-by":"publisher","first-page":"124825","DOI":"10.1016\/j.saa.2024.124825","volume":"322","author":"T Alomar","year":"2024","unstructured":"Alomar, T., AlMasoud, N. & Mansour, F. R. A green method for the Preparation of carbon quantum Dots from yellow lupin Peel waste for spectrofluorometric determination of nirmatrelvir. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 322, 124825 (2024).","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"9904_CR30","doi-asserted-by":"crossref","unstructured":"Akca, Z., \u00d6ZOK, H. \u0130., Yardim, Y. & \u015eent\u00fcrk, Z. J. T. J. C. Electroanalytical investigation and voltammetric quantification of antiviral drug favipiravir in the pharmaceutical formulation and urine sample using a glassy carbon electrode in anionic surfactant media, 46 869\u2013880. (2022).","DOI":"10.55730\/1300-0527.3375"},{"key":"9904_CR31","doi-asserted-by":"crossref","unstructured":"Tkach, V. V. et al. J.B.R.i.A Theoretical description for anti-COVID-19 drug Remdesivir electrochemical determination, assisted by squaraine Dye\u2013Ag2O2 composite, 11 9201\u20139208. (2021).","DOI":"10.33263\/BRIAC112.92019208"},{"key":"9904_CR32","doi-asserted-by":"crossref","unstructured":"Nabil, A. et al. A green voltammetric determination of molnupiravir using a disposable Screen-Printed reduced graphene oxide electrode: application for pharmaceutical dosage and biological fluid forms, 11 471. (2023).","DOI":"10.3390\/chemosensors11090471"},{"key":"9904_CR33","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/jccs.200700213","volume":"54","author":"N Rahman","year":"2007","unstructured":"Rahman, N., Haque, S. M. & Azmi, S. N. H. Kinetic spectrophotometric determination of Metoprolol tartrate in commercial dosage forms. J. Chin. Chem. Soc. 54, 1511\u20131520 (2007).","journal-title":"J. Chin. Chem. Soc."},{"key":"9904_CR34","doi-asserted-by":"publisher","first-page":"451967","DOI":"10.1155\/2009\/451967","volume":"6","author":"R Singh Gujral","year":"2009","unstructured":"Singh Gujral, R., Manirul Haque, S. & Shanker, P. A sensitive UV spectrophotometric method for the determination of Gabapentin. J. Chem. 6, 451967 (2009).","journal-title":"J. Chem."},{"key":"9904_CR35","doi-asserted-by":"publisher","first-page":"219430","DOI":"10.1155\/2009\/219430","volume":"6","author":"RS Gujral","year":"2009","unstructured":"Gujral, R. S., Haque, S. M. & Shanker, P. A sensitive validated spectrophotometric method for the determination of Flucloxacillin sodium. J. Chem. 6, 219430 (2009).","journal-title":"J. Chem."},{"key":"9904_CR36","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.scp.2023.101193","volume":"35","author":"SKM Haque","year":"2023","unstructured":"Haque, S. K. M. et al. Charge transfer based green spectrophotometric method to determine remogliflozin etabonate applying response surface methodology supported with computational studies in pharmaceutical formulations. Sustainable Chem. Pharm. 35, 101193 (2023).","journal-title":"Sustainable Chem. Pharm."},{"key":"9904_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s13369-022-06782-w","volume":"48","author":"SK Manirul Haque","year":"2023","unstructured":"Manirul Haque, S. K. Validated kinetic spectrophotometric methods to optimize robustness study with Youden factorial combinations to determine repaglinide using response surface methodology via Box\u2013Behnken design. Arab. J. Sci. Eng. 48, 129\u2013144 (2023).","journal-title":"Arab. J. Sci. Eng."},{"key":"9904_CR38","doi-asserted-by":"crossref","unstructured":"Azmi, S. N. H. et al. Box\u2013Behnken Design Based Development of UV-Reversed Phase High Performance Liquid Chromatographic Method for Determination of Ascorbic Acid in Tablet Formulations,Separations,9 361. (2022).","DOI":"10.3390\/separations9110361"},{"key":"9904_CR39","doi-asserted-by":"publisher","first-page":"118708","DOI":"10.1016\/j.molliq.2022.118708","volume":"352","author":"SKM Haque","year":"2022","unstructured":"Haque, S. K. M. Box\u2013Behnken experimental design for optimizing the HPLC method to determine Hydrochlorothiazide in pharmaceutical formulations and biological fluid. J. Mol. Liq. 352, 118708 (2022).","journal-title":"J. Mol. Liq."},{"key":"9904_CR40","first-page":"116553","volume":"149","author":"W Wojnowski","year":"2022","unstructured":"Wojnowski, W., Tobiszewski, M. & Pena-Pereira, F. E.J.T.T.i.A.C. Psillakis. AGREEprep\u2013analytical Greenness Metr. Sample Preparation. 149, 116553 (2022).","journal-title":"AGREEprep\u2013analytical Greenness Metr. Sample Preparation"},{"key":"9904_CR41","doi-asserted-by":"publisher","first-page":"100025","DOI":"10.1016\/j.sampre.2022.100025","volume":"3","author":"F Pena-Pereira","year":"2022","unstructured":"Pena-Pereira, F., Tobiszewski, M., Wojnowski, W. & Psillakis, E. A tutorial on agreeprep an analytical greenness metric for sample Preparation. Adv. Sample Preparation. 3, 100025 (2022).","journal-title":"Adv. Sample Preparation"},{"key":"9904_CR42","doi-asserted-by":"crossref","unstructured":"MansourF.R., P\u0142otka-Wasylka, J. & Locatelli, M. Modified GAPI (MoGAPI) tool and software for the assessment of method greenness: case studies and applications. Analytica 5, 451\u2013457 (2024).","DOI":"10.3390\/analytica5030030"},{"key":"9904_CR43","doi-asserted-by":"crossref","unstructured":"Manousi, N., Wojnowski, W., P\u0142otka-Wasylka, J. & Samanidou, V. J. G. Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality, 25 7598\u20137604. (2023).","DOI":"10.1039\/D3GC02347H"},{"key":"9904_CR44","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.sampre.2025.100164","volume":"14","author":"FR Mansour","year":"2025","unstructured":"Mansour, F. R., Bedair, A. & Locatelli, M. Click analytical chemistry index as a novel concept and framework, supported with open source software to assess analytical methods. Adv. Sample Preparation. 14, 100164 (2025).","journal-title":"Adv. Sample Preparation"},{"key":"9904_CR45","unstructured":"Guideline, I. C. H. Validation of Analytical Procedures Q2 (R2) (ICH: Geneva, 2022)."},{"key":"9904_CR46","unstructured":"Guidance, R. Validation of chromatographic methods, Center for Drug Evaluation and Research (CDER), Washington, 2 (1994)."},{"key":"9904_CR47","doi-asserted-by":"crossref","unstructured":"Sharaf, Y. A., El Deeb, S., Ibrahim, A. E., Al-Harrasi, A. & Sayed, R. A. J. M. Two green micellar HPLC and mathematically assisted UV spectroscopic methods for the simultaneous determination of molnupiravir and favipiravir as a novel combined COVID-19 antiviral regimen, 27 2330. (2022).","DOI":"10.3390\/molecules27072330"},{"key":"9904_CR48","unstructured":"Illendula, S., Sindhuja, P. L., Suresh, C. V. & Rao, K. A NOVEL VALIDATED RP-HPLC METHOD FOR THE ESTIMATION OF REMDESIVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM."},{"key":"9904_CR49","doi-asserted-by":"crossref","unstructured":"Imam, M. S., Batubara, A. S., Gamal, M., Abdelazim, A. H. & Almrasy, A. A. S.J.S.r. Ramzy, adjusted green HPLC determination of nirmatrelvir and Ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations, 13 137. (2023).","DOI":"10.1038\/s41598-022-26944-y"},{"key":"9904_CR50","doi-asserted-by":"publisher","first-page":"139143","DOI":"10.1016\/j.molstruc.2024.139143","volume":"1317","author":"SKM Haque","year":"2024","unstructured":"Haque, S. K. M., Abu-Judeh, A., Jain, R. & Kabir, A. Greener spectrophotometric and HPLC investigation of CNS agent pregabalin: Taguchi model and box-behnken design for method parameters optimization. J. Mol. Struct. 1317, 139143 (2024).","journal-title":"J. Mol. Struct."},{"key":"9904_CR51","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1007\/s42250-024-01131-w","volume":"7","author":"SKM Haque","year":"2024","unstructured":"Haque, S. K. M. et al. Design of experiment (DoE), screening and optimization of system variables to develop and validate greener spectrophotometric investigation of repaglinide. Chem. Afr. 7, 5225\u20135243 (2024).","journal-title":"Chem. Afr."},{"key":"9904_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12247-024-09828-8","volume":"19","author":"SKM Haque","year":"2024","unstructured":"Haque, S. K. M. et al. The application of Box-Behnken-Design in the optimization of kinetic spectrophotometry and computational studies to determine and assessing Eco-Scale to green analytical chemistry for labetalol. J. Pharm. Innov. 19, 28 (2024).","journal-title":"J. Pharm. Innov."},{"key":"9904_CR53","doi-asserted-by":"publisher","first-page":"9667","DOI":"10.1007\/s13369-024-09023-4","volume":"49","author":"SKM Haque","year":"2024","unstructured":"Haque, S. K. M. et al. Greener High-Performance liquid Chromatography\u2014Supported with computational studies to determine empagliflozin: Box\u2013Behnken design and Taguchi model for optimization. Arab. J. Sci. Eng. 49, 9667\u20139689 (2024).","journal-title":"Arab. J. Sci. Eng."},{"key":"9904_CR54","doi-asserted-by":"publisher","first-page":"122805","DOI":"10.1016\/j.saa.2023.122805","volume":"298","author":"SKM Haque","year":"2023","unstructured":"Haque, S. K. M., Kabir, A., Rahman, N. & Azmi, S. N. H. Response surface methodology combined Box-Behnken design optimized green kinetic spectrophotometric and HPLC methods to quantify angiotensin receptor blocker Valsartan in pharmaceutical formulations. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 298, 122805 (2023).","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"9904_CR55","doi-asserted-by":"publisher","first-page":"108191","DOI":"10.1016\/j.microc.2022.108191","volume":"184","author":"SM Haque","year":"2023","unstructured":"Haque, S. M. et al. Application of Box\u2013Behnken design combined response surface methodology to optimize HPLC and spectrophotometric techniques for quantifying febuxostat in pharmaceutical formulations and spiked wastewater samples. Microchem. J. 184, 108191 (2023).","journal-title":"Microchem. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09904-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09904-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09904-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:48:02Z","timestamp":1757238482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09904-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9904"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09904-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"25470"}}